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Abstract
Background: Perfluoroalkyl acids are synthetic compounds widely used in industrial and commercial applications.
Laboratory studies suggest that these persistent and bioaccumulative chemicals produce oxidant stress and
damage glomerular endothelial cells, raising concern regarding the impact of these compounds on renal function.
Methods: We performed cross-sectional analyses of data 1960 participants aged 12–19 years of the 2003–2010
National Health and Nutrition Examination Surveys. PFAA exposure was assessed using levels of perfluorooctane
sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid, and perfluorohexane sulfonic acid.
Primary study outcomes were estimated glomerular filtration rate (eGFR) and serum uric acid.
Results: While adjusting for demographics, cotinine, prehypertension, insulin resistance, body mass index, and
hypercholesterolemia, adolescents in the highest PFOA and PFOS quartile had a lower eGFR, 6.84 mL/min/1.73 m2
(95 % CI: 2.19 to 11.48) and 9.69 mL/min/1.73 m2 (95 % CI: -4.59 to 14.78), respectively, compared to the lowest
quartile. Highest PFOA and PFOS quartiles were also associated with 0.21 mg/dL (95 % CI: 0.056 to 0.37) and
0.19 mg/dL (95 % CI: 0.032 to 0.34) increases in uric acid, respectively.
Conclusions: PFAAs are associated with a reduction in kidney function and increased uric acid levels in otherwise
healthy adolescents. Reverse causation and residual confounding could explain the results. Our study results
confirm and amplify previous findings, though longitudinal studies examining prenatal and childhood biomarkers in
relationship with robust measures of childhood renal function are needed.
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Background
Perfluoroalkyl acids (PFAAs) are synthetic organic com-
pounds with a totally fluorinated carbon chain of varying
length and a negatively charged functional group, such
as carboxylic or sulfonic acid [1]. This imparts high sta-
bility and thermal resistance to these compounds.
PFAAs have found wide utility when polymerized in
stain-resistant sprays for carpets and upholstery, fire-
retarding foams, and nonstick cooking surfaces and food
packaging, such as microwave popcorn bags and pizza
packaging [2]. National biomonitoring surveys reveal
that >98 % of the US population have detectable levels
of PFAAs in the blood including: perfluorooctane sul-
fonic acid (PFOS), perfluorooctanoic acid (PFOA), per-
fluorohexane sulfonate (PFHxS) and perfluorononanoic
acid (PFNA) [3].
In cell culture studies, exposure of microvascular
endothelial cells to PFOS induces endothelial permeabil-
ity through increased production of reactive oxidative
species at concentrations relevant to human exposures
[4]. This is important given that endothelial cells are
vital to structure and function of the glomeruli in the
kidney. Furthermore, endothelial permeability plays a
critical role in ischemic renal injury [5]. The effect of
PFOA, PFOS, PFNA and PFHxS on the kidneys is fur-
ther magnified by the fact that these compounds are well
absorbed orally but have poor renal elimination rates
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and half-lives in humans of 2.3-8.5 years [6]. Children
and adolescents are uniquely vulnerable to PFOA and
PFOS as they have greater food consumption per pound
body weight [7]. PFAAs are present in human breast
milk, and serum levels in children are generally higher
than in adults [6, 8]. Childhood exposure may present
the additional risk of disrupting cardiovascular and renal
physiologic functions, and so vulnerability may be
greater than in adults.
Cross-sectional studies have associated PFAA bio-
markers with reduced renal function. In one recent
large, community-based study of residents living near a
fluoropolymer production facility which resulted in con-
tamination of their drinking water with elevated PFOA,
serum PFOA, PFOS, PFNA and PFHxS concentrations
were inversely correlated with estimated glomerular fil-
tration rate (eGFR) in otherwise healthy children and ad-
olescents [9]. A study by Shankar et al revealed similar
findings in adults [10]. The study also found that PFOA
and PFOS were associated with increased odds of
chronic kidney disease (CKD), defined as eGFR <60 ml/
min/1.73 m2 [10].
Several cross-sectional epidemiological studies in adults
and children have also shown a positive association be-
tween PFOA and uric acid (UA) [10–13], though one failed
to detect such an association [14]. This is relevant since hy-
peruricemia has long been thought to be an important
marker of renal disease. Moreover, growing evidence sug-
gests that hyperuricemia may be part of the causal pathway
in the development of hypertension. Numerous clinical
studies have shown that elevated UA levels are associated
with increased risk of hypertension, independent of other
risk factors [15–18]. UA levels >5.5 mg/dL were observed
in 90 % of adolescents with essential hypertension, whereas
UA levels were significantly lower in controls and teens
with either white-coat or secondary hypertension [16].
Finally, hyperuricemia is an independent risk factor for dis-
ease progression in pediatric patients with CKD [19].
However, studies to date have not explored the associ-
ation between low grade exposure to perfluoroalkyl che-
micals in the range commonly experienced by children/
adolescents and kidney function. Therefore, we exam-
ined the association of PFAAs with kidney function i.e.,
eGFR and uric acid in a nationally representative sample
of US adolescents. We sought to test the hypothesis that
higher levels of exposure to PFAAs would be associated
with a decrement in kidney function and an increment
in serum uric acid concentration.
Methods
The current study is based on eight years of data (2003–
2010) of 12–19 year olds enrolled in the National Health
and Nutrition Examination Survey (NHANES), a continu-
ous, multicomponent, nationally representative survey of
the non-institutionalized US population administered by
the National Center for Health Statistics (NCHS) of the
Centers for Disease Control and Prevention (CDC). Data
from questionnaire, laboratory, diet, and physical examin-
ation components were used in the present analysis, for
which data are available in biennial groupings. NHANES
oversamples low-income persons, African-Americans, and
Mexican-Americans in order to provide stable estimates
of these groups. For participants <18 years of age, in-
formed assent was obtained from the participants and
informed consent was obtained from the parents or
guardians. The survey also includes biomonitoring for
perfluoroalkyl chemicals in a random one-third sub-
sample of participants by CDC’s National Center for
Environmental Health.
Exposure measurements
Perfluoroalkyl chemicals were measured in serum using
automated solid-phase extraction coupled to isotope di-
lution high-performance liquid-chromatography-tandem
mass spectrometry (details summarized elsewhere [20]).
Although our study examined all twelve PFAAs surveyed
by NHANES, we primarily focused on PFOA, PFOS,
PFNA and PFHxS, which were detected in over 97 % of
participants. Values below the limit of detection were
reported as the limit of detection divided by square root
of 2.
Measures of outcome
Serum creatinine (Cr) was measured using the modified
kinetic Jaffe reaction on two different instruments over
the study period: the Beckman Coulter Synchron LX20
(Beckman Coulter, Fullerton, California) in NHANES
2003–2007 [21], and the Beckman Coulter UniCel®
DxC800 in NHANES 2008–10. A crossover study per-
formed on a subsample during the instrumentation
change, from the Beckman Synchron LX-20 to the Beck-
man Coulter UniCel® DxC800, revealed the 2007 serum
Cr values were slightly higher than the 2008 values. The
2003–2007 Cr values were therefore reduced by
0.08 mg/dL ensuring comparability in the results over
the entire study period [22]. In addition, CDC regularly
cross-references results to a “gold standard” reference as
recommended by the National Kidney Disease Education
Program [23]. A comparison of the mean Cr levels of
NHANES 2005–06 revealed significant differences be-
tween the two methods, requiring additional calibration
of the uncorrected values by the following equation: [24]
Corrected Crð20052006Þ ¼ 0:016þ 0:978 
ðNHANES uncalibrated serum Cr ðmg=dLÞ
Because serum Cr was measured using the Jaffe reac-
tion during the entire study period, we used the original
Kataria et al. Environmental Health  (2015) 14:89 Page 2 of 13
Schwartz formula, which has been validated as a meas-
ure of kidney function in adolescents, to calculate eGFR
(mL/min/1.73 m2) [25].
UA was measured using the Beckman Synchron LX20
system in NHANES 2003–2007 and Beckman Coulter
UniCel® DxC800 in NHANES 2008–2010. Detailed la-
boratory procedures for the other analytes including
cholesterol and cotinine are available on the CDC web-
site [26, 27]. Although measurements were conducted
on different instrumentation, CDC has not recom-
mended any corrections. To account for possible con-
founding by instrumentation method, sensitivity analyses
reprised all multivariable analyses by including a covari-
ate for NHANES two-year wave of data collection.
Potential confounders
We included and adjusted for various potential con-
founders in our multivariable regression models. Height
and weight information was collected by trained techni-
cians following standardized procedures. BMI z-scores
were derived using CDC 2000 norms, incorporating
height, weight and age and values >95th percentile was
defined as obese [28].
Blood pressure (BP) was measured by certified exam-
iners 3 times in all children aged 8–19 years after 5 min
of resting in a sitting position. In cases with 1 or more
incomplete or interrupted measurements, a fourth at-
tempt was made. Averages of systolic (SBP) and diastolic
BP (DBP) measurements were calculated for the purpose
of generating categorical BP variables. As BP varies
widely by age, sex, and height, we calculated systolic and
diastolic BP z-scores from mixed-effects linear regres-
sion models derived using data from 1999–2000 CDC
NHANES. We input sex, age, and height z-scores de-
rived from CDC norms to compute expected SBP and
DBP [28]. BP z-scores were then calculated from the
measured BP using the formula z = (x−μ)/σ, where x is
the measured BP, μ is the 50th percentile BP, and σ is de-
rived from the same NHANES data [29]. We categorized
BP outcomes as present or absent prehypertension (BP
≥90th percentile for age/height z-score/sex).
Age, Sex, race/ethnicity, caregiver’s level of education
and income were assessed using a questionnaire. Race/
ethnicity was categorized into Mexican American, other
Hispanic, Non- Hispanic white, non-Hispanic black, and
other, based on self-report by 17- to 19- year-olds and
caregiver report in 12–16-year-olds. Poverty to income
ratio (PIR), calculated by dividing family income by the
federal poverty level for family size, was categorized into
quartiles. Pregnancy status was assessed through ques-
tionnaire and urine pregnancy status; pregnant partici-
pants were excluded from our study.
Other measures came from laboratory assessments. In-
sulin resistance was included in the analyses, as studies
have shown insulin resistance to be associated with
hypertension and higher UA in children [30]. To assess
insulin resistance, we calculated homeostatic model as-
sessment of insulin resistance (HOMA-IR) by multiply-
ing fasting insulin and glucose divided by 22.5. Insulin
resistance was analyzed as categorical outcome, using
the cut point of 4.39, which is more than 2 SD above the
mean HOMA-IR for normal-weight adolescents with
normal fasting glucose in NHANES 1999–2002 [31].
Since exposure to tobacco smoke is thought to be a risk
factor for kidney disease in adolescents, serum cotinine
was also included in the analyses [32]. Cotinine levels
were categorized into low (<0.15 ng/mL), medium
(≥0.15 ng/mL and >2.0 ng/mL) and high (≥2.0 ng/mL)
[33]. Total cholesterol was considered as a potential co-
variate as lowering cholesterol has been shown to reduce
the rate of kidney function loss [34]. Total cholesterol
was categorized into low or high groups using the cut-
point of 170 mg/dL, based on published guidelines [35].
To maximize sample size in multivariable analysis,
missing categories were created for all potential con-
founders except high cholesterol and BMI category (both
n = 1). Less than 10 % of values were missing for any
confounding variable, except in case of insulin resistance
category, which had 51 % of values missing.
Statistical analysis
Univariable, bivariate and appropriately weighted multi-
variable analyses were conducted in a fashion that re-
flects the complex survey sampling design, using Stata
13.0 (College Station, TX) survey (‘svy’) commands. Bi-
variate analyses were performed for the sum of all 12
PFAAs to explore potential confounding in PFAA-
outcome relationships.
Substantial (>40 %) non-detectable concentrations
were identified for 8 of the 12 PFAA. Given the substan-
tial frequency of non-detectable concentrations for the
other PFAAs, our analyses focused on PFOA, PFOS,
PFHxS and PFNA in the population with available eGFR
data. Outcome variables eGFR and UA were analyzed as
continuous variables for multivariable analyses. To fur-
ther confirm the findings, eGFR and UA were catego-
rized into quartile for ordered logistic regression, which
is used to predict the odds of categorical severity of the
abnormality based on the values of the predictor
variables.
Multivariable linear regressions were performed to
examine the association between increasing PFAA quar-
tiles and differences in eGFR and UA, adjusting for race/
ethnicity, sex, poverty-income ratio, caregiver education,
serum cotinine, prehypertension, insulin resistance, BMI,
and hypercholesterolemia categories.
We performed sensitivity analyses by adding an
NHANES wave covariate to account for confounding by
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UA measurement method. Finally, given that PFAAs are
potential endocrine disruptors [36], we also conducted
sex-stratified analyses to assess potential interactions.
Because hypercholesterolemia may be an intermediate
factor in the causal pathway between PFAAs exposure
and renal dysfunction, sensitivity analyses also reprised
models without adjustment for cholesterol. Sensitivity
analyses also examined addition of continuous age, and
substitution of BMI Z-score for categorical body mass.
Change of regression coefficients by >10 % or attenu-
ation statistical significance was used in these sensitivity
analyses as criteria for suggesting modification of effects.
Finally, we identified in our statistical analyses that
PFAA concentrations are strongly correlated with each
other. Upon identifying associations of PFOS and PFOA
with primary outcomes, in an effort to delineate which
of the two were driving effects on renal function, we per-
formed multivariable regressions that simultaneously ex-
amined PFOS and PFOA.
Results
During the study period, 7,168 children and adolescents
participated. There were 1961 non-pregnant participants
for whom serum perfluoroalkyl concentrations were
available. We excluded one participant who had eGFR
<60 mL/min/1.73 m2, resulting in 1960 participants,
with 54.3 % male (Table 1). Mean Cr, eGFR and UA
were 0.74 ± 0.17 mg/dL, 144.0 ± 27.6 mL/min/1.73 m2
and 5.07 ± 1.19 mg/dL, respectively.
Univariate analyses of renal outcomes against quartiled
PFAAs revealed substantial differences among those more
highly exposed, with strongest associations for PFOS.
Compared with the lowest PFOS levels, all three higher
quartiles had lower eGFR with 6.31 (95 % CI:−11.1 to
−1.49), 6.56 (95 % CI:−12.0 to−1.06) and 9.76 (95 %
CI:−15.1 to−4.44) mL/min/1.73 m2 decrements. Adoles-
cents with the highest PFOA concentrations had 4.37 mL/
min/1.73 m2 lower eGFR (95 % CI:−9.15 to 0.40). No sig-
nificant associations with PFHxS or PFNA were identified.
Bivariate analyses revealed substantial differences in
PFAAs, eGFR and uric acid by social, behavioral and other
characteristics (Appendix Tables 3 and 4), supporting po-
tential confounding and inclusion of covariates in multi-
variable models. Non-Hispanic white and non-Hispanic
black participants had significantly higher mean creatinine
and lower eGFR. Obesity was associated with significantly
lower creatinine, higher eGFR and higher uric acid levels.
Insulin resistance was also associated with lower creatin-
ine, higher eGFR and higher uric acid levels. High levels of
cotinine (>2 ng/mL) were associated with significantly in-
creased creatinine and uric acid and decreased eGFR. Pre-
hypertension and high total cholesterol were found to be
associated with significantly increased uric acid level but
not with creatinine and eGFR. Participants with caregivers
who had 9–12th grade education, high school/graduate
equivalency diploma or college/Associate’s degree had sig-
nificantly higher creatinine and lower eGFR than those
with less than 9th grade or college and greater education.
Bivariate analyses of PFAAs revealed males to have
higher total PFAA than female. Non-Hispanic whites and
non-Hispanic blacks had total PFAA levels in the 4th quar-
tile more frequently than other race/ethnicities. Highest





Male 1064 (54.3 %)
Female 896 (45.7 %)
Mean Age ± SD 15.5 ± 2.3
Race, n (%)
Mexican American 589 (30 %)
Other Hispanics 139 (7.1 %)
Non-Hispanic white 546 (27.9 %)
Non-Hispanic black 594 (30.3 %)
Other race 92 (4.7 %)
Poverty to income ratio, n (%)
First Quartile (<0.78) 423 (21.6 %)
Second quartile (0.78 to1.45) 449 (22.9 %)
Third Quartile (1.46 to 2.92) 467 (23.8 %)
Fourth Quartile (>2.92) 495 (25.3 %)
Missing 126 (6.4 %)
Parent/Caregiver Education Level, n (%)
Less than 9th grade 262 (13.4 %)
9-12th grade 372 (19.0 %)
High school Grad/GED 459 (23.4 %)
College or AA degree 522 (26.6 %)
College or greater 259 (13.2 %)
Unknown 86 (4.4 %)
Serum Cotinine, n (%)
< 0.015 ng/mL 312 (15.9 %)
0.015–1.9 ng/mL 1284 (65.5 %)
At least 2.0 ng/mL 364 (18.6 %)
High Cholesterol, n (%) 647 (33.1 %)
Obese, n (%) 429 (21.9 %)
Insulin resistant 195 (20.3 %)
BP >90th percentile 151 (7.93 %)
Median Creatinine, mg/dL (IQR) 0.72 (0.62, 0.86)
Median eGFR, min/mL/1.73 m2 (IQR) 140.4 (125.1, 158.8)
Mean Uric Acid, mg/dL (IQR) 5.0 (4.2, 5.8)
IQR interquartile range, eGFR estimated glomerular filtration rate
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total PFAA quartile was also correlated with increasing
quartiles of cotinine levels, worsening poverty-income ra-
tio and higher education level of parent/caregivers. On the
other hand, obesity and insulin resistance were associated
with lower total PFAA quartiles. Age, high total choles-
terol and prehypertension did not have significant associa-
tions with total PFAA levels.
Upon control for potential confounders, multivariable
linear regression revealed adolescents in the highest
quartile of PFOA to have 6.61 mL/min/1.73 m2 lower
eGFR than adolescents in the lowest quartile (95 % CI:
-11.39 to−1.83, Table 2). Similarly, when examining the
relationship between PFOS and eGFR, the multivariable
regression revealed a negative correlation such that all
higher quartiles of PFOS are associated with a statisti-
cally significant decrease in eGFR quartile, compared to
the lowest quartile. Most notably, quartile 4 of PFOS
was associated with a 9.47 mL/min/1.73 m2 lower eGFR
(95 % CI:−14.68 to−4.25). Results for eGFR and UA were
non-significant for PFHxS and PFNA.
The highest PFOA and PFOS quartile were also asso-
ciated with a 0.21 mg/dL (p = 0.009) and 0.19 mg/dL (p
= 0.019) increase in UA levels compared with lowest
quartile, respectively (Table 2). Multivariable analyses
failed to show any significant associations of PFHxS and
PFNA with any of the outcome variables.
Ordered logistic regression revealed that increasing
PFOS quartiles were associated with significant decrease
in eGFR, with adolescents in highest PFOS quartile hav-
ing a 1.96-fold higher risk of having eGFR in the lower
quartiles (95 % CI: 1.37, 2.86; p < 0.001). Adolescents in
the highest PFOA and PFOS quartiles had significantly
increased risk of having UA in higher quartiles, com-
pared to those in the lower PFOA/PFOS quartiles (Ap-
pendix Table 6).
Sex-stratified regression models did not alter associa-
tions of PFAA with eGFR or UA measures, and addition
of NHANES two-year wave covariate failed to change re-
gression coefficients by >10 % or attenuate statistical sig-
nificance. Sensitivity analyses also reprised models without
adjustment for cholesterol (Appendix Table 5), and failed
to find a change in regression coefficients by >10 % or at-
tenuate statistical significance. Sensitivity analyses failed to
find significant alteration of associations resulting from
addition of continuous age, or substitution of BMI Z-
score for categorical body mass.
Table 2 Multivariable regression of perfluoroalkyl acids with outcome measure of kidney function
eGFR (min/mL/1.73 m2) Uric Acid (mg/dL)
Increment (95 % CI) Increment (95 % CI)
Perfluorooctanoic acid (PFOA)
Quartile 1 (<2.5 ng/mL) Reference Reference
Quartile 2 (2.5–3.5 ng/mL) −2.63 (−7.07 to 1.81) 0.17 (−0.033 to 0.37)
Quartile 3 (3.5–4.7 ng/mL −5.42 (−11.46 to 0.61) 0.13 (−0.030 to 0.28)
Quartile 4 (≥4.7 ng/mL) −6.61 (−11.39 to−1.83)** 0.21 (0.056 to 0.37)**
Perfluorooctane sulfonic acid (PFOS)
Quartile 1 (<7.9 ng/mL) Reference Reference
Quartile 2 (7.9–12.8 ng/mL) −5.24 (−9.75 to−0.73)* 0.095 (−0.081 to 0.27)
Quartile 3 (12.8 19.4 ng/mL) −7.21 (−12.21 to−2.21)** 0.046 (−0.10 to 0.19)
Quartile 4 (≥19.4 ng/mL) −9.47 (−14.68 to−4.25)*** 0.19 (0.032 to 0.34)*
Perfluorononanoic Acid (PFNA)
Quartile 1 (<0.7 ng/mL) Reference Reference
Quartile 2 (0.7–1.0 ng/mL) 1.24 (−4.29 to 6.78) 0.013 (−0.17 to 0.20)
Quartile 3 (1.0–1.5 ng/mL) 2.76 (−1.68 to 7.20) −0.035 (−0.20 to 0.13)
Quartile 4 (≥1.5 ng/mL) −1.06 (−5.49 to 3.37) 0.12 (−0.051 to 0.29)
Perfluorohexane Sulfonic acid (PFHxS)
Quartile 1 (<1 ng/mL) Reference Reference
Quartile 2 (1–2 ng/mL) 1.37 (−3.59 to 6.34) 0.040 (−0.14 to 0.22)
Quartile 3 (2–3.95 ng/mL) 1.85 (−3.36 to 7.05) 0.053 (−0.13 to 0.23)
Quartile 4 (≥4 ng/mL) −0.32 (−4.44 to 3.81) −0.054 (−0.22 to 0.11)
All models adjust for Sex, poverty-income ratio, caregiver education, serum cotinine, prehypertension, insulin resistance, Body Mass Index, hypercholesterolemia
and race/ethnicity categories
Conversion factors for units: serum creatinine in mg/dL to μmol/L, ×88.4; serum uric acid in mg/dL to μmol/L, x59.48
eGFR estimated glomerular filtration rate
* p < 0.05 ** p < 0.01 *** p < 0.001
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Finally, PFOA was substantially correlated with PFOS
(r = 0.60). Simultaneous examination of PFOA and PFOS
revealed significant decrements in eGFR and increases
in uric acid in association with PFOA but not PFOS.
Compared with the lowest quartile, adolescents with
higher levels of PFOA had 3.90 (95 % CI:−8.04 to 0.24),
5.84 (95 % CI:−11.56 to−0.12) and 5.77 (95 % CI:−11.01
to 0.54) mL/min/1.73 m2 lower eGFR. Compared with
the lowest quartile, adolescents with higher levels of
PFOA had 0.20 (95 % CI: 0.02 to 0.39), 0.15 (95 %
CI:−0.006 to 0.32) and 0.23 (95 % CI: 0.02 to 0.43) mg/
dL higher uric acid.
Discussion
In a representative sample of 1960 US adolescents, we
found higher concentrations of PFOA and PFOS, but not
PFHxS or PFNA in serum to be associated with a decre-
ments in eGFR and increases in UA, independent of nu-
merous confounders including demographic features, other
environmental exposures and lifestyle variables. All the stat-
istical analyses, including evaluating exposures as categor-
ical variables by quartiles and ordered logistic regression,
indicate that graded exposure to these chemicals is associ-
ated with reductions in eGFR and UA. These results are
consistent with previous cross-sectional studies, including a
community-based study of adolescents exposed to PFOA-
contaminated water, and cross-sectional study of adult
NHANES participants [9–11, 13]. The smaller decrement
in eGFR (<1 mL/min/1.73 m2) in a much more highly ex-
posed sample compared with our estimates (7−10 mL/min/
1.73 m2) suggests the possibility of steeper dose-response
relationship in the lower ranges of exposure, which has also
been identified for lead [37], PFAAs [38] and other environ-
mental chemicals though we cannot exclude residual con-
founding. A steeper dose-response curve at lower exposure
ranges for various endpoints has also been found for
PFAAs (including PFOA and PFOS) for several endpoints
including liver enzymes, cholesterol, and UA [12, 39, 40]. In
addition, the relationship between PFAA exposure and
eGFR may be more apparent in adolescents with normal
kidney function compared to adults who may have subclin-
ical renal disease.
Evidence from animal studies suggests the association
between PFAAs and renal function is biologically plaus-
ible. The finding of renal hypertrophy and histopatho-
logical alterations indicate that cell proliferation and
injury occur in rats exposed to PFOA and PFOS, likely
induced by reactive oxidative species [4, 41]. These rat
models exhibited generally higher concentrations of
PFOS in all organs compared to PFOA, likely due to
slower elimination of PFOS. This may explain the rela-
tively stronger associations with PFOS observed in our
study [41]. One preclinical study has suggested that early
life exposure to PFAA could produce elevated blood
pressure [42].
Increases in serum UA concentration could potentially
be part of the causal pathway between PFAAs and eGFR
given that it is a potent pro-oxidant in the intracellular
environment and induces oxidative stress and endothe-
lial dysfunction. The net effect of high UA levels may be
development of hypertension, interstitial fibrosis, glo-
merulosclerosis and eventual kidney failure [43]. The
mechanisms underlying the association between hyper-
uricemia and PFAAs are not clear. PFAAs may compete
with anion transporters that are normally responsible for
UA secretion, ultimately resulting in decreased UA ex-
cretion [44]. Alternatively, since UA is renally cleared,
higher UA levels could also be the consequence of de-
creased kidney function due to PFAA exposure. Further
mechanistic studies are needed to clarify the biological
association between UA and PFAAs.
While all our participants had normal renal function,
the 7−10 mL/min/1.73 m2 decrease in eGFR observed
with higher levels of the compounds is not insignificant.
Moreover, studies of essential hypertension in children
have shown that for each 1 mg/dl change in UA, there is
an associated average increase of 14 mmHg in systolic
blood pressure and 7 mmHg in diastolic blood pressure
[16]. Slight increases in serum uric acid concentration
within the normal range, comparable to changes noted
in our study, have been associated with a larger decline
in GFR and a higher incidence of CKD over a 2-year
period in a community-based adult Japanese cohort [45].
The increase in UA that we documented in association
with PFAA exposure may lead to a change in blood
pressure that may be important on a population level.
Given the prolonged half-life of these chemicals, levels
of PFAAs in these adolescents are likely to persist into
adulthood, and so the impact of these compounds on
renal function is likely magnified as the chemicals in-
duce oxidant stress over an extended period of time. As
these children age, their renal functional reserve dimin-
ishes, and so in the context of exposure to other poten-
tial environmental toxins or conditions, the rate of their
kidney dysfunction may be accelerated, increasing the
risk of CKD.
Reverse causality is a major limitation of our study, and
could represent an alternate explanation of our findings,
in that serum PFAAs could be higher simply because of
reduced excretion. While we note the C8 panel finding
that there is not a probable link between PFOA exposure
and kidney disease [46], the unique vulnerability of chil-
dren to PFAAs has not been studied longitudinally, let
alone in the lower ranges of exposure in whom steeper
dose-response relationships are noted. Could a 5−10 %
difference in renal function (a 7-10 mL/min/1.73 m2 dec-
rement from a median of 140.4) produce a twofold
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increase in PFAA? While this is a possibility, the present
evidence cannot provide definitive proof that it does. In-
deed, the serum concentration of most molecules that are
cleared by the kidney does not begin to rise until the GFR
falls below 60–90 ml/min/1.73 m2.
In one recent large, community based study of residents
living near a production facility exposed to contaminated
water, serum PFAA levels were inversely correlated with
eGFR in otherwise healthy children and adolescents [9].
The authors of this paper argue that curve attenuation
may indicate reverse causation. However, curve attenu-
ation at higher dose has characterized the findings of
many known outcome relationships with toxins (or drugs)
that interact with nuclear receptors [47], and could ex-
plain the differential findings between the NHANES
population and the population living near a production fa-
cility. PFOS concentrations are affected by human entero-
hepatic factors [48, 49], yet Watkins et al found PFOS to
be strongly associated with eGFR.
Han et al note that organic anion transporters in the
proximal tubule cells result in the secretion and then re-
absorption of these compounds [50]. Some use these data
together with null findings about antecedent PFAA expos-
ure described by Watkins et al [9] to postulate that the site
of renal dysfunction is tubular rather than glomerular. We
have made no a priori assumption on the primary site of
injury within the kidney. Based on what is known about
the ability of PFAAs to induce oxidant stress, both glom-
eruli and tubules are equally plausible as targets of PFAA-
induced renal injury and both would result in a decline in
GFR. We could not study tubular function in the
NHANES sample, and believe that an optimal study
would longitudinally measure both glomerular and tubu-
lar function, potentially adjusting for the latter. The Wat-
kins study did not adjust for tubular function.
Watkins et al describes a highly exposed sample (me-
dian PFOA fourfold higher than the lower margin of the
highest quartile in our sample) in which antecedent expo-
sures were modeled from resident address and water mea-
surements, with modest predictive value in children
(62 %) [9]. Biomarker data were not available prior to
measured renal function. While some might argue that
the Watkins et al study proves reverse causation, a single
study cannot result in such a conclusion, just as forward
causation cannot be determined from a single study. Al-
though our study results are incremental in that they
chiefly confirm and amplify previous findings, they sup-
port the need for better longitudinal study with serially
collected biomarker data.
There are a few other limitations to the study includ-
ing the cross-sectional nature of this study, which pre-
vents us from inferring causality. Other limitations
include lack of data on potential confounders such as
diet, family history of kidney disease and Tanner staging,
as PFAAs are known to have estrogenic activity [36, 51].
We were also unable to control for other environmental
chemicals which are oxidant stressors and have been as-
sociated with albuminuria and cardiorenal risks [52–54].
We could not ascertain the degree to which the PFAAs
were albumin bound as opposed to freely circulating,
which may vary among individuals and contribute to the
interindividual differences in renal function associated
with PFAAs in this study [55]. While increased binding
might mitigate the nephrotoxic effects of PFAAs, re-
duced protein binding might result in greater uptake by
renal cells and exacerbate injury.
We also note that the Schwartz formula is but one
measure of glomerular function. We also could not exam-
ine the albumin-to-creatinine ratio, because in children,
only first morning voids yield valid measurements, and
these were only available in NHANES 2009–10. Measure-
ments of Cystatin C have led to development of alternate
formulas, and as have other formulas using beta-trace pro-
tein [56]. Beyond glomerular function, tubular function
could not be assessed in our study.
Our study suggests perfluoroalkyl chemicals present as
modifiable risk factors for kidney dysfunction that could
be eliminated with a voluntary phase out of the four
PFAAs that remains on target to complete a phase-out
by 2015 [57]. Given their persistence in the environ-
ment, continued formation from precursor compounds,
and the potential for continued production by non-
participating manufacturers in the U.S. and/or overseas,
environmental contamination and human exposure with
the potential for health impacts from these PFAAs is ex-
pected to continue even after they are phased out, as
seen in the case of PFOS. Furthermore, numerous
PFAAs continue to be used. A Swedish study of PFAA
trends between 1996–2010 confirmed increases in
PFHxS (4.3 %/year), but also noted 11 % increases/year
of a four-carbon PFAA, perfluoroalkylbutane sulfonate
(PFBS), a substitute for PFOS increasingly found in food.
[58] These findings suggest that the adverse effects of
PFAAs on kidney function in children and adolescents
will continue to represent a potential health problem in
the coming years. Longitudinal research is therefore
highly relevant, both to clarify the observed associations
of eGFR and UA with PFAAs, and ongoing efforts to re-
duce long-term health effects of PFAA exposure.
Conclusions
In this cross-sectional study of healthy adolescents, we
found levels of PFOA and PFOS to be significantly associ-
ated with decreased kidney function within the normal
range and increased serum UA levels. Prospective studies
are needed to confirm the association and understand bio-
logical mechanisms underlying this relationship.
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Appendix










Overall 1961 0.75 95.7 142.9 301.8
Sex
Male 1064 0.81 P < 0.001 90.9 P < 0.001 149.7 P < 0.001 333.8 P < 0.001
Female 897 0.68 101.3 134.9 263.7
Age
12 233 0.60 110.8 147.5 270.4 P < 0.001
13 249 0.64 P < 0.001 107.0 P < 0.001 163.3 P < 0.001 283.1
14 258 0.71 98.9 150.9 301.0
15 227 0.76 93.8 143.4 311.4
16 246 0.81 90.5 137.0 309.3
17 244 0.81 89.0 136.4 314.9
18 267 0.82 87.8 131.9 311.9
19 237 0.82 88.2 133.0 310.9
Race/Ethnicity
Mexican American 589 0.70 Reference 99.9 Reference 147.9 Reference 299.4 Reference
Other Hispanics 139 0.70 P < 0.876 101.1 P < 0.516 151.0 P < 0.224 305.7 P < 0.354
Non-Hispanic white 547 0.77 P < 0.001 95.2 P < 0.001 143.5 P < 0.005 314.0 P < 0.001
Non-Hispanic black 594 0.79 P < 0.001 90.2 P < 0.001 135.2 P < 0.001 292.1 P < 0.073
Other race 92 0.72 P < 0.499 98.4 P < 0.451 144.6 P < 0.279 300.4 P < 0.899
Poverty to Income Ratio
First Quartile (<0.78) 423 0.75 Reference 95.5 Reference 141.3 Reference 305.2 Reference
Second quartile (0.78 to1.45) 449 0.74 P < 0.591 95.4 P < 0.941 141.6 P < 0.837 295.1 P < 0.035
Third Quartile (>1.46 to 2.92) 468 0.75 P < 0.898 96.1 P < 0.633 144.5 P < 0.079 300.6 P < 0.335
Fourth Quartile (>2.92) 495 0.75 P < 0.590 95.4 P < 0.930 143.7 P < 0.176 306.2 P < 0.825
Missing 126 0.75 P < 0.873 96.2 P < 0.705 143.9 P < 0.341 300.8 P < 0.536
Parent/Caregiver Education Level
Less than 9th grade 263 0.71 Reference 100.3 Reference 147.5 Reference 299.8 Reference
9-12th grade 372 0.74 P < 0.044 95.4 P < 0.001 142.3 P < 0.019 299.9 P < 0.978
High school Grad/GED 459 0.77 P < 0.001 93.9 P < 0.001 141.9 P < 0.008 304.2 P < 0.420
College or AA degree 522 0.76 P < 0.001 94.8 P < 0.001 141.9 P < 0.007 303.1 P < 0.537
College or greater 259 0.74 P < 0.048 96.3 P < 0.015 142.2 P < 0.028 297.9 P < 0.766
Unknown 86 0.75 P < 0.076 95.3 P < 0.032 144.9 P < 0.432 306.7 P < 0.428
Serum Cotinine
< 0.015 ng/mL 312 0.69 Reference 102.2 Reference 148.5 Reference 284.1 Reference
0.015-1.9 ng/mL 1284 0.74 P < 0.001 96.6 P < 0.001 143.9 P < 0.007 299.0 P < 0.001
≥ 2.0 ng/mL 365 0.85 P < 0.001 86.9 P < 0.001 134.8 P < 0.001 326.7 P < 0.001
High Cholesterol
Total Cholesterol < 170 mg/dL 1312 0.74 P < 0.310 96.1 P < 0.115 144.1 P < 0.005 298.1 P < 0.001
Total Cholesterol≥ 170 mg/dL 648 0.75 94.7 140.4 309.0
Obesity Status
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Table 3 Mean creatinine, eGFR and uric acid, by sample characteristics (Continued)
Not Obese 1531 0.75 P < 0.016 94.8 P < 0.001 141.6 P < 0.001 290.9 P < 0.00
Obese 429 0.73 98.7 147.4 340.3
Insulin Status
HOMA-IR <4.39 767 0.76 P < 0.009 95.2 P < 0.001 142.4 P < 0.001 295.4 P < 0.001
HOMA-IR ≥4.39 195 0.71 101.1 150.3 337.4
Blood Pressure Status
Blood Pressure <90th Percentile 1752 0.75 P < 0.503 95.4 P < 0.353 142.5 P < 0.272 300.2 P < 0.006
Blood Pressure ≥90th Percentile 151 0.74 96.9 145.0 316.5
Table 4 Bivariate analysis of total serum of perfluoroalkyl acids by demographics, anthropometric and clinical characteristics
Total Perfluoroalkyl Acids










Overall 490 (25.0 %) 487 (24.8 %) 494 (25.2 %) 490 (25.0 %)
Sex
Male 211 (19.8 %) 234 (22.0 %) 294 (27.6 %) 325 (30.6 %) P < 0.001
Female 279 (31.1 %) 253 (28.2 %) 200 (22.3 %) 165 (18.4 %)
Race
Mexican American 205 (34.8 %) 168 (28.5 %) 121 (20.5 %) 95 (16.1 %) P < 0.001
Other Hispanics 68 (48.9 %) 33 (23.7 %) 26 (18.7 %) 12 (8.6 %)
Non-Hispanic white 84 (15.4 %) 128 (23.4 %) 160 (29.3 %) 175 (32.0 %)
Non-Hispanic black 107 (18.0 %) 136 (22.9 %) 169 (28.5 %) 182 (30.6 %)
Other race 26 (28.3 %) 22 (23.9 %) 18 (19.6 %) 26 (28.3 %)
Poverty to Income Ratio
First Quartile (<0.78) 138 (32.6 %) 101 (23.9 %) 98 (23.2 %) 86 (20.3 %) P < 0.001
Second quartile (0.78 to1.45) 133 (29.6 %) 104 (23.2 %) 116 (25.8 %) 96 (21.4 %)
Third Quartile (>1.46 to 2.92) 99 (21.25) 120 (25.6 %) 126 (26.9 %) 123 (26.3 %)
Fourth Quartile (>2.92) 82 (16.6 %) 130 (26.3 %) 125 (25.3 %) 158 (31.9 %)
Missing 38 (30.2 %) 32 (25.4 %) 29 (23.0 %) 27 (21.4 %)
Parent/Caregiver Education
Less than 9th grade 112 (42.6 %) 77 (29.3 %) 49 (18.6 %) 25 (9.5 %) P < 0.001
9-12th grade 94 (25.3 %) 98 (26.3 %) 110 (29.6 %) 70 (18.8 %)
High school Graduate or GED 105 (22.9 %) 109 (23.7 %) 118 (25.7 %) 127 (27.7 %)
College or AA degree 101 (19.4 %) 106 (20.3 %) 142 (27.2 %) 173 (33.1 %)
College graduate or greater 54 (20.9 %) 72 (27.8 %) 56 (21.6 %) 77 (29.7 %)
Unknown 24 (27.9 %) 25 (29.1 %) 19 (22.1 %) 18 (20.1 %)
Serum Cotinine
< 0.015 ng/mL 103 (33.0 %) 76 (24.4 %) 68 (21.8 %) 65 (20.8 %) P < 0.001
0.015–1.9 ng/mL 336 (26.2 %) 312 (24.3 %) 320 (24.9 %) 316 (24.6 %)
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Table 5 Multivariable regression of perfluoroalkyl acids with outcome measure of kidney function unadjusted for cholesterol
Creatinine (mg/dL) eGFR (min/mL/1.73 m2) Uric Acid (mg/dL)
Perfluorooctanoic acid (PFOA)
Quartile 1 (<2.5 ng/mL) Reference Reference Reference
Quartile 2 (2.5–3.5 ng/mL) 0.007 (−0.012 to 0.027) −2.81 (−7.16 to 1.53) 0.17 (–0.028 to 0.37)
Quartile 3 (3.5–4.7 ng/mL 0.021 (−0.008 to 0.050) −5.50 (−11.50 to 0.50) 0.13 (−0.030 to 0.29)
Quartile 4 (≥4.7 ng/mL) 0.029 (0.004 to 0.054)* −6.84 (−11.48 to−2.19)** 0.23 (0.071 to 0.39)**
Perfluorooctane sulfonic acid (PFOS)
Quartile 1 (<7.9 ng/mL) Reference Reference Reference
Quartile 2 (7.9–12.8 ng/mL) 0.021 (−0.007 to 0.049) −5.39 (−9.87 to−0.92)* 0.11 (−0.063 to 0.29)
Quartile 3 (12.8 19.4 ng/mL) 0.038 (0.008 to 0.068)* −7.25 (−12.25 to−2.25)** 0.045 (−0.10 to 0.19)
Quartile 4 (≥19.4 ng/mL) 0.040 (0.010 to 0.071)** −9.69 (−14.78 to−4.59)*** 0.20 (0.041 to 0.35)*
Perfluorononanoic Acid (PFNA)
Quartile 1 (<0.7 ng/mL) Reference Reference Reference
Quartile 2 (0.7–1.0 ng/mL) −0.003 (−0.035 to 0.029) 1.25 (−4.30 to 6.80) 0.011 (−0.17 to 0.19)
Quartile 3 (1.0–1.5 ng/mL) −0.018 (−0.046 to 0.009) 2.59 (−1.89 to 7.08) −0.027 (−0.19 to 0.14)
Quartile 4 (≥1.5 ng/mL) 0.0034 (−0.24 to 0.031) −1.2 (−5.62 to 3.22) 0.13 (−0.035 to 0.30)
Perfluorohexane Sulfonic acid (PFHxS)
Quartile 1 (<1 ng/mL) Reference Reference Reference
Quartile 2 (1–2 ng/mL) −0.000 (−0.029 to 0.029) 1.27 (−3.67 to 6.21) 0.053 (−0.12 to 0.23)
Quartile 3 (2–3.95 ng/mL) −0.007 (−0.037 to 0.023) 1.81 (−3.40 to 7.03) 0.052 (−0.13 to 0.23)
Quartile 4 (≥4 ng/mL) −0.008 (−0.036 to 0.020) −0.31 (−4.39 to 3.77) −0.057 (–0.23 to 0.11)
All models adjust for gender, poverty-income ratio, caregiver education, serum cotinine, prehypertension, insulin resistance, Body Mass Index, and
race/ethnicity categories
Conversion factors for units: serum creatinine in mg/dL to μmol/L, ×88.4; serum uric acid in mg/dL to μmol/L, x59.48
eGFR estimated glomerular filtration rate
* p < 0.05 ** p < 0.01 *** p < 0.001
Table 4 Bivariate analysis of total serum of perfluoroalkyl acids by demographics, anthropometric and clinical characteristics
(Continued)
≥ 2.0 ng/mL 51 (14.0 %) 99 (27.1 %) 106 (29 %) 109 (29.9 %)
High Cholesterol
Total Cholesterol < 170 mg/dL 345 (26.3 %) 331 (25.2 %) 327 (24.9 %) 309 (23.6 %) P < 0.097
Total Cholesterol≥ 170 mg/dL 145 (22.4 %) 156 (24.1 %) 166 (25.6 %) 181 (27.9 %)
Obesity Status
Not Obese 365 (23.8 %) 366 (23.9 %) 399 (20.1 %) 401 (26.25) P < 0.007
Obese 125 (29.1 %) 120 (28 %) 95 (22.1 %) 89 (20.8 %)
Insulin Status
HOMA-IR <4.39 191 (24.9 %) 178 (23.2 %) 208 (27.1 %) 190 (24.8 %) P < 0.001
HOMA-IR ≥4.39 70 (35.9 %) 58 (29.7 %) 36 (18.5 %) 31 (15.9 %)
Blood Pressure Status
Blood Pressure <90th Percentile 437 (24.9 %) 433 (24.7 %) 441 (25.2 %) 441 (25.2 %) P < 0.674
Blood Pressure ≥90th Percentile 37 (24.5 %) 44 (29.1 %) 35 (23.2 %) 35 (23.2 %)
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